We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Supplemental new drug application (sNDA) has been approved for an expanded indication of MYCAMINE® for the treatment of invasive candidiasis in paediatric patients under four months old.
The US Food and Drug Administration (FDA) has approved Astellas Pharma’s supplemental New Drug Application (sNDA) for Mycamine (micafungin for injection).